{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T13:56:11Z","timestamp":1721224571682},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1016\/j.clinthera.2007.05.001","type":"journal-article","created":{"date-parts":[[2007,8,14]],"date-time":"2007-08-14T11:23:25Z","timestamp":1187090605000},"page":"814-822","source":"Crossref","is-referenced-by-count":7,"title":["Comparison of inhibition of cutaneous histamine reaction of ebastine fast-dissolving tablet (20 mg) versus desloratadine capsule (5 mg): A randomized, double-blind, double-dummy, placebo-controlled, three-period crossover study in healthy, nonatopic adults"],"prefix":"10.1016","volume":"29","author":[{"given":"Rosa","family":"Antonijoan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Consuelo","family":"Garc\u00eda-Gea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Puntes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joselin","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram\u00f3n","family":"Esbr\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Serra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Fortea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel J.","family":"Barbanoj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2007.05.001_bib1","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1517\/14656566.5.8.1807","article-title":"A review of the second-generation antihistamine ebastine for the treat ment of allergic disorders","volume":"5","author":"Van Cauwenberge","year":"2004","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2007.05.001_bib2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2165\/00003495-199600521-00006","article-title":"Clinical studies of the efficacy and tolerability of ebastine 10 or 20 mg once daily in the treatment of seasonal allergic rhinitis in the US","volume":"52","author":"Storms","year":"1996","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2007.05.001_bib3","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1177\/009127002401382696","article-title":"A double-blind, placebo-controlled study of the efficacy and safety of ebastine 20 mg once daily given with and without food in the treatment of seasonal allergic rhinitis","volume":"42","author":"Frank","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2007.05.001_bib4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1358\/mf.2003.25.2.723684","article-title":"Efficacy of ebastine in the control of nasal congestion associated with allergic rhinitis","volume":"25","author":"Ratner","year":"2003","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2007.05.001_bib5","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1159\/000077357","article-title":"Efficacy and safety of ebastine 20 mg compared to loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis: A randomized, double-blind, placebo-controlled study","volume":"133","author":"Ratner","year":"2004","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.clinthera.2007.05.001_bib6","first-page":"615","article-title":"Ebastine in perennial allergic rhinitis","volume":"67","author":"Picado Valles","year":"1991","journal-title":"Ann Allergy"},{"key":"10.1016\/j.clinthera.2007.05.001_bib7","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1034\/j.1398-9995.1999.00984.x","article-title":"A 12-week, placebocontrolled study of the efficacy and safety of ebastine, 10 and 20 mg once daily, in the treatment of perennial allergic rhinitis","volume":"54","author":"Bousquet","year":"1999","journal-title":"Allergy"},{"key":"10.1016\/j.clinthera.2007.05.001_bib8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3109\/09546639109086774","article-title":"Ebastine in chronic urticaria: A double-blind placebo controlled study","volume":"2","author":"Peyr\u00ed","year":"1991","journal-title":"J Dermatol Treat"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2007.05.001_bib9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2165\/00003495-199600521-00008","article-title":"Double-blind multicentre comparative study of ebastine, terfenadine and placebo in the treatment of chronic idiopathic urticaria in adults","volume":"52","author":"Kalis","year":"1996","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2007.05.001_bib10","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1081-1206(10)63269-3","article-title":"Comparison of ebastine to cetirizine in seasonal allergic rhinitis in adults","volume":"76","author":"Gehanno","year":"1996","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.clinthera.2007.05.001_bib11","first-page":"56","article-title":"A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ebastine (20 mg and 10 mg) to loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis","volume":"14","author":"Hampel","year":"2004","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.clinthera.2007.05.001_bib12","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1067\/mai.2000.105525","article-title":"Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treat ment of seasonal allergic rhinitis","volume":"105","author":"Ratner","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2007.05.001_bib13","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1159\/000088869","article-title":"Meta-analysis of the efficacy of ebastine 20 mg compared to loratadine 10 mg and placebo in the symptomatic treatment of seasonal allergic rhinitis","volume":"138","author":"Ratner","year":"2005","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.clinthera.2007.05.001_bib14","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-2125.1988.tb05288.x","article-title":"The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine in healthy subjects","volume":"26","author":"Vincent","year":"1988","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2007.05.001_bib15","doi-asserted-by":"crossref","first-page":"981","DOI":"10.2165\/00003495-200059040-00018","article-title":"Ebastine: An update of its use in allergic disorders","volume":"59","author":"Hurst","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2007.05.001_bib16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/00003088-200443020-00004","article-title":"Pharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: A phase I openlabel study","volume":"43","author":"Lasseter","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2007.05.001_bib17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1046\/j.0306-5251.2001.01345.x","article-title":"Effects of supratherapeutic doses of ebastine and terfena dine on the QT interval [published correction appears in Br J Clin Pharmacol. 2001;52:343]","volume":"52","author":"Gillen","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2007.05.001_bib18","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1046\/j.0306-5251.2002.01661.x","article-title":"Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval","volume":"54","author":"Malik","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2007.05.001_bib19","series-title":"Presented at: InterasmaEAACI Joint Meeting","article-title":"Phase I, single dose, open-label, randomized, crossover bioequivalence studies of ebastine 10 and 20 mg fast-dissolving tablets in healthy male volunteers","author":"Salva","year":"2004"},{"key":"10.1016\/j.clinthera.2007.05.001_bib20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/00044011-200121010-00004","article-title":"Efficacy and tolerability of oncedaily 5mg desloratadine, an H1-receptor antagonist, in patients with seasonal allergic rhinitis: Assessment during the spring and fall allergy seasons","volume":"21","author":"Meltzer","year":"2001","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.clinthera.2007.05.001_bib21","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003088-199528050-00006","article-title":"Pharmacokinetic-pharmacodynamic relationships of H1-antihistamines","volume":"28","author":"Desager","year":"1995","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2007.05.001_bib22","doi-asserted-by":"crossref","first-page":"S385","DOI":"10.1016\/S0091-6749(00)91552-5","article-title":"Dose-proportionality, linearity, and pharmacokinetics of deslorata dine in healthy adults","volume":"105","author":"Herron","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2007.05.001_bib23","series-title":"Allergy: Principles and Practice","first-page":"430","article-title":"In-vivo methods for study of allergy, skin tests: Techniques and interpreta tion","author":"Demoly","year":"1998"},{"key":"10.1016\/j.clinthera.2007.05.001_bib24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000074308","article-title":"A study comparing the inhibitory effects of single and repeated oral doses of ebastine and fexofenadine against histamine-induced skin reactivity","volume":"132","author":"Barbanoj","year":"2003","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.clinthera.2007.05.001_bib25","series-title":"Description of Patient-Rated General Symptom Scales. Comparative Evaluation of Rating Scales for Clinical Pharmacology","first-page":"59","year":"1988"},{"key":"10.1016\/j.clinthera.2007.05.001_bib26","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/0091-6749(87)90292-2","article-title":"Skin test reactivity to histamine from infancy to old age","volume":"80","author":"Skassa-Brociek","year":"1987","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2007.05.001_bib27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000233664","article-title":"Effect of skin pigmentation on the response to intradermal histamine","volume":"76","author":"Van Niekerk","year":"1985","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"10.1016\/j.clinthera.2007.05.001_bib28","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1472-8206.2000.tb00423.x","article-title":"Activity of ebastine (10 and 20 mg) and cetirizine at 24 hours of a steady treatment in the skin of healthy volunteers","volume":"14","author":"Frossard","year":"2000","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2007.05.001_bib29","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1034\/j.1398-9995.1999.00032.x","article-title":"A double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: Suppression of histamineinduced wheal and flare response for 24 h in healthy male subjects","volume":"54","author":"Grant","year":"1999","journal-title":"Allergy"},{"key":"10.1016\/j.clinthera.2007.05.001_bib30","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000080959","article-title":"Central and peripheral evaluation of rupatadine, a new antihistamine\/platelet-activating factor antagonist, at different doses in healthy volunteers","volume":"50","author":"Barbanoj","year":"2004","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.clinthera.2007.05.001_bib31","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1081-1206(10)61952-7","article-title":"Efficacy of ebastine, cetirizine, and loratadine in histamine cutane ous challenges","volume":"89","author":"Gispert","year":"2002","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.clinthera.2007.05.001_bib32","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v21.i6.10","article-title":"Orally fast disintegrating tablets: Developments, technologies, taste-masking and clinical studies","volume":"21","author":"Fu","year":"2004","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"10.1016\/j.clinthera.2007.05.001_bib33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/hup.741","article-title":"Evaluation of the cognitive, psychomotor and pharma cokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers","volume":"21","author":"Barbanoj","year":"2006","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.clinthera.2007.05.001_bib34","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1016\/S0091-6749(97)70128-3","article-title":"Appraisal of the validity of histamine-induced wheal and flare to predict the clinical efficacy of antihistamines","volume":"99","author":"Monroe","year":"1997","journal-title":"J Allergy Clin Immunol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291807001191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291807001191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,15]],"date-time":"2018-06-15T22:23:50Z","timestamp":1529101430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291807001191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S0149291807001191"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2007.05.001","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}